{"url_path":"/sec/mplt/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224129-index.html","accession_number":"0001193125-26-224129","cik":"0001770069","ticker":"MPLT","issuer_name":"MapLight Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224129-index.html","primary_entity_key":"0001770069","primary_entity_name":"MapLight Therapeutics, Inc."},"word_count":115,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.\n\n(a) Sales of Unregistered Securities\n\nNone.\n\n(b) Use of Proceeds from Public Offering of Common Stock\n\nOn October 26, 2025, our Registration Statement on Form S-1, as amended (File No. 333-290400), for our initial public offering, or the IPO, became effective, pursuant to which we sold an aggregate of 16,962,500 shares of our common stock for net proceeds of $261.6 million. There has been no material change in the planned use of proceeds from our IPO as described in our prospectus filed pursuant to Rule 424(b)(3) under the Securities Act with the SEC on October 27, 2025.\n\n(c) Issuer Purchases of Equity Securities\n\nNone."}